In rheumatoid arthritis a randomized trial reported a 4-year major adverse cardiovascular events (MACE) of 3.4% with tofacitinib 5 mg BID and 4.2% with 10 mg BID, compared with 2.5% with anti-TNF therapy, with higher risk in patients ≥ 65 years or with prior atherosclerotic cardiovascular disease [84]. The gene discussed is TNF; the disease is rheumatoid arthritis.